ClinicalTrials.gg
CompletedNCT01880216Updated Feb 4, 2016

Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT

A Phase 3 interventional study of Bemiparin sodium and Enoxaparin sodium in Deep Vein Thrombosis, sponsored by Berlin-Chemie AG Menarini Group. Completed at 25 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-02-04.

Sponsored by Berlin-Chemie AG Menarini Group (part of Menarini Group) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Venous Thrombosis with a site in Russian Federation — 1 open to participants now, 1 under way, none of them phase 3. Venous Thrombosis · Russian Federation.

Enrollment
24th of 28
312 · median 1,036
Started
2013
with 1 other
Phase 3
20 of 32
none open now
Registered
19th of 32
by date
Lead sponsor
1 of 32
Berlin-Chemie AG Menarini Group

Among the 32 studies in Venous Thrombosis with a site in Russian Federation, this one is the 24th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2013, is one of 20 in phase 3, and was the 19th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

1 of the 32 studies in Venous Thrombosis with a site in Russian Federation is open now. Recruiting first, the newest first:

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Venous Thrombosis with a site in Russian Federation, or all of them as a file.
02

Study summary

Deep-vein thrombosis (DVT) is a common but under-diagnosed medical condition that occurs when a thrombus forms in one of the large veins, usually in the lower limbs, leading to either partial or complete blocked circulation. The condition may progress to severe health complications, such as pulmonary embolism (PE), if not diagnosed and treated in a timely and effective manner.

The goal of the therapy for lower-extremity DVT is to prevent the extension of thrombus and pulmonary embolism in the short term and to prevent recurrent events in the long-term. Although anticoagulant therapy decreases the risk of recurrent thrombosis, the treatment also increases the risk for major hemorrhage.

This trial aims to optimize the current medical knowledge on the effectiveness and safety of two low molecular weight heparins, bemiparin and enoxaparin in the treatment of deep vein thrombosis.

Read the detailed description

The aim of this study is to demonstrate the therapeutic non-inferiority of bemiparin sodium (LMWH) versus enoxaparin sodium (LMWH) during a 7±2 days treatment period and a follow up of 11 weeks observation period.

Primary endpoint:

The percentage of patients with an improvement in thrombotic burden at Visit 3 (Day 83) defined as a ≥4-point reduction in thrombus score (or at least halving the thrombus score, when the total score is ≤ 6), without confirmed symptomatic extension of recurrence of DVT, confirmed symptomatic PE, or VTE-related death at Visit 3 (Day 83 / Month 3), as measured by complete compression ultrasound (cCUS) by Duplex sonography according to a standardized protocol.

Secondary endpoint:

The secondary efficacy endpoints are defined as the:

  • Incidence of symptomatic venous thromboembolic events (VTE) at Visit 3 (Day 83:
  • Recurrent DVT
  • Pulmonary embolism

Incusion criteria:

Patients with acute deep-vein thrombosis of the leg (DVT) with symptoms of less than 14 days, confirmed by complete compression ultrasound (cCUS) within 48 hours prior study start.

Patients who have given their signed declaration of consent and data protection declaration Males and females aged 18 years

03

Conditions studied

  • Deep Vein Thrombosis

Browse trials for

Keywords

  • Deep vein thrombosis
  • DVT
  • Treatment
  • Low molecular weight heparin
  • Bemiparin
  • Enoxaparin
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with acute deep-vein thrombosis of the leg (DVT) with symptoms of less than 14 days confirmed by complete compression ultrasound (cCUS) within 48 h prior study starting .
  2. Males and females aged ≥18 years
  3. Patients who have given their written .

Exclusion criteria

Exclusion Criteria:

Specific

  1. History and presence of familial bleeding diathesis, presence of active bleeding contraindicating anticoagulant therapy, as well as presence of coagulation - and clotting factor disorder,and thrombocytopenia
  2. Patients having undergone thrombectomy, having had insertion of a caval filter or who were treated with a fibrinolytic agent to treat the current episode of DVT
  3. Treatment with heparin (fractionated or unfractionated), fondaparinux or vitamin K antagonist or warfarin for treatment of DVT for more than 48 h prior to enrolment
  4. Long-term treatment with vitamin K antagonists, i.e. for atrial fibrillation, myocardial infarction or cardiomyopathy
  5. Isolated distal calf vein thrombosis
  6. Isolated superficial vein thrombosis
  7. Any other symptomatic venous thromboembolism beside of DVT
  8. Known to heparin (including other pig-derived substances), to the study medications and heparin-derivatives including other LMWHs, warfarin and/or to the active ingredient or any of the study medications
  9. Concurrent treatment with function inhibitors (such as acetylsalicylic acid, ticlopidine, clopidogrel, NSAID), fibrinolytic agents and other anticoagulant agents, Glycoprotein IIb/IIIa receptor- antagonists, nitro-glycerine iv, systemic , penicillin in high doses, dextran, ascorbic acid, digitalis, tetracycline, medical products that could increase the potassium plasma level
  10. History of documented or suspected heparin-induced thrombocytopenia (HIT I and II) or platelet count less than 100,000 platelets per mm3
  11. Ischaemic stroke one month prior to enrolment
  12. History of or active intracranial disorder (cerebral vascular aneurysm, arterio-venous malformation or cerebral neoplasm), history of haemorrhagic stroke or other intracranial bleeding 6 months prior to enrolment, active haemorrhage or increased risk of bleeding due to impaired haemostatics or organ lesion (e.g. peptic ulcer, hepatic failure, haemorrhagic stroke, macroscopic visible urogenital bleeding, cerebral vascular aneurysm or cerebral neoplasm) 1 month prior to enrolment.
  13. Uncontrolled arterial hypertension: systolic blood pressure > 200 mmHg and diastolic blood pressure > 105 mmHg.
  14. Severe impairment of pancreas function, history of gastro-duodenal ulcer disease, nephrolithiasis and/or ureterolithiasis, choroid and retinal vascular disease, suspected vascular retinopathy, vitreous haemorrhage or other intraocular bleedings, or any organic lesion with an increased risk of bleeding.
  15. Significant liver disease (e.g. acute hepatitis, chronic active hepatitis, hepatic cirrhosis, hepatic encephalopathy) or liver enzymes ( and/or AST) > 5x .

and others

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
312 participants (actual)

Study arms

  • Active comparator
    Enoxaparin sodium

    subcutaneous for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin

    Drug: Enoxaparin sodium

  • Experimental
    Bemiprin sodium

    Bemiparin sodium (LMWH) s.c. for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin

    Drug: Bemiparin sodium

Interventions

  • subcutaneous application daily for 7±2 days

    Also known as: LMWH; CAS 874-98-4

  • subcutaneous for 7±2 days

    Also known as: LMWH; CAS 73334-07-3

06

What researchers measure

Primary outcomes

  1. Percentage of patients with an improvement in thrombotic burden at Visit 3

    Time frame: 83±7 days

Secondary outcomes

  1. Incidence of symptomatic venous thromboembolic events (VTE)

    Time frame: 83±7 days

Other outcomes

  1. Treatment emergent adverse events (TEAEs)

    Time frame: 83±7 days

07

Study locations

25 sites
  • Unimed Ajara LLC
    Batumi, 6000, Georgia
  • Angiology and Vascular Surgery Academic Clinic
    Tbilisi, 0112, Georgia
  • Bokhua Clinic of Angiology and Heart Diseases
    Tbilisi, 0159, Georgia
  • G. Chapidze Emergency Cardiology Centre
    Tbilisi, 0159, Georgia
  • Aversi Clinic
    Tbilisi, 0177, Georgia
  • Regional State Budget Institution of Healthcare "Regional Clinical Hospital"
    Barnaul, Russian Federation
  • Federal State Budgetary Institution "Scientific Center of Reconstructive and Restorative Surgery" under Siberian Branch of the Russian Academy of Medical Sciences on the clinical base of State Institution of Healthcare, Irkutsk Regional Clinical Hospital
    Irkutsk, 664079, Russian Federation
  • State Healthcare Institution "Republican Clinical hospital of the ministry of Health of Republic Tatarstan
    Kazan, 420097, Russian Federation
  • State Budget Public Health Institution of Moscow "City Clinical Hospital # 1 n.a. N.I. Pirogov"
    Moscow, 117049, Russian Federation
  • Federal Government Healthcare Institution "Hospital of the Russian Federation Internal Affairs Ministry in Moscow"
    Moscow, 127299, Russian Federation
  • Federally Funded State Institution "Institute of Surgery n.a. A.V. Vishnevskiy of the Ministry of Healthcare of Russian Federation"
    Moscow, 305035, Russian Federation
  • State-Financed Healthcare Institution of the Novosibirsk Region "City Clinical Hospital # 2"
    Novosibirsk, 630051, Russian Federation
  • State Budgetary Institution of the Omsk Region "Regional Clinical Hospital"
    Omsk, 664111, Russian Federation
  • State Independent Healthcare Institution of the Perm kray "City Clinical Hospital # 4"
    Perm, 614107, Russian Federation
  • State Budget Institution of Hifger Professional Education "Rostov State Medical University" of the Ministry of the Russian Federation
    Rostov-on-Don, 344022, Russian Federation
  • State Budgetary Institution of the Ryazan Region "Regional Clinical Cardiologic Dispensary"
    Ryazan, 117997, Russian Federation
  • State Budget Institution "St.Petersburg Janelidze Research Institute of Emergency Medicine"
    Saint-Petersburg, 192242, Russian Federation
  • St. Petersburg State Public Health Institution "City Multi-field Hospital #2"
    Saint-Petersburg, 194354, Russian Federation
  • Nongovernmental Public Health Institution " Road Clinical Hospital" of Russian Railways
    Saint-Petersburg, 195271, Russian Federation
  • State Educational Institution of Additional Professional Education "St.Petersburg Medical Academy of Postgraduate Education of Federal Agency for Health Care and Social Development", Chair of cardiovascular surgery
    Saint-Petersburg, 195427, Russian Federation
  • St. Petersburg State Public Health Institution "City Hospital #26"
    Saint-Petersburg, 196247, Russian Federation
  • Federal State Budgetary Institution "Russian Center of Emergency and Radiation Medicine n.a. A.M. Nikiforov" of the Ministry of Russian Federation for Civil Defence, Emergencies and Elimination of Consequences of Natural Disasters
    Saint-Petersburg, 197374, Russian Federation
  • State budgetary institution of higher professional education "Samara State Medical University"
    Samara, 443099, Russian Federation
  • State Budget Public Health Institution of Yaroslavl region "Clinical hospital #10", Municipal Clinical Public Health Institution " Medical Unit of Novo-Yaroslavl Petroleum Refinery"
    Yaroslavl, 150023, Russian Federation
  • State Budget Public Health Institution of Yaroslavl Region "Regional Clinical Hospital"
    Yaroslavl, 150062, Russian Federation
08

References and documents

Publications

  • Suchkov IA, Martinez-Gonzalez J, Schellong SM, Garbade T, Falciani M; Bemiparin DVT Study Group. Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial. Clin Drug Investig. 2018 Feb;38(2):181-189. doi: 10.1007/s40261-017-0600-6. PubMed 29214507 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jan 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2013
First posted
Jun 18, 2013
Start
Jun 2013
Primary completionActual
Jan 2015
CompletionActual
May 2015
Last update
Feb 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01880216
Responsible party
Sponsor
First posted
Jun 18, 2013
Start date
Jun 2013
Primary completion
Jan 2015
Completion
May 2015
Last update
Feb 4, 2016

Study contacts

Maria Th Kaltwasser, Dr.
study chair · Berlin-Chemie AG

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexketoprofen

Start the discussion